149 related articles for article (PubMed ID: 8555495)
1. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
Ong F; Kaiser U; Seelen PJ; Hermans J; Wijermans PW; de Kieviet W; Jaques G; Kluin-Nelemans JC
Blood; 1996 Jan; 87(2):712-6. PubMed ID: 8555495
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
4. Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma.
Ong F; Hermans J; Noordijk EM; De Kieviet W; Seelen PJ; Wijermans PW; Kluin-Nelemans JC
Leuk Lymphoma; 1997 Nov; 27(5-6):495-501. PubMed ID: 9477131
[TBL] [Abstract][Full Text] [Related]
5. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
[TBL] [Abstract][Full Text] [Related]
6. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.
Ely SA; Knowles DM
Am J Pathol; 2002 Apr; 160(4):1293-9. PubMed ID: 11943714
[TBL] [Abstract][Full Text] [Related]
8. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders.
Smith SR; Auerbach B; Morgan L
Br J Haematol; 1996 Jan; 92(1):67-70. PubMed ID: 8562413
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
Bataille R; Boccadoro M; Klein B; Durie B; Pileri A
Blood; 1992 Aug; 80(3):733-7. PubMed ID: 1638024
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
11. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
13. Serum beta 2 microglobulin in multiple myeloma and related plasma cell dyscrasias.
Pasquini E; Tiraferri E; Fattori PP; Fabbri I; Gobbi M
Haematologica; 1987; 72(1):17-21. PubMed ID: 3108090
[No Abstract] [Full Text] [Related]
14. Bone remodelation markers are useful in the management of monoclonal gammopathies.
Hernández JM; Suquía B; Queizan JA; Fisac RM; Sanchez JJ; Fernández-Calvo FJ; García-Sanz R; Olivier C; Bárez A; Calmuntia MJ; García-Frade J; Portero JA; López R; Aguilera C; Navajo JA; San-Miguel JF
Hematol J; 2004; 5(6):480-8. PubMed ID: 15570289
[TBL] [Abstract][Full Text] [Related]
15. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma.
Schaar CG; Kaiser U; Snijder S; Ong F; Hermans J; Franck PF; Kluin-Nelemans JC
Br J Haematol; 1999 Oct; 107(1):132-8. PubMed ID: 10520033
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
18. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
[TBL] [Abstract][Full Text] [Related]
19. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance.
Diamond T; Levy S; Smith A; Day P; Manoharan A
Intern Med J; 2001 Jul; 31(5):272-8. PubMed ID: 11512598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
